MP
TEVA icon

Manifold Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Manifold Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-1,610
Closed -$63K – 127
2013
Q2 		$63K Buy
+1,610
New +$62.7K 0.04% 83

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

Manifold Partners's TEVA Position: Q3 2013 in Review

Manifold Partners sold out of Teva Pharmaceuticals (TEVA) in Q3 2013, closing a stake of 1,610 shares — an estimated $63K sold.

Manifold Partners first reported a position in TEVA in Q2 2013 and held it in 1 quarter. The position peaked at $63K in Q2 2013. 705 funds tracked by Wall St. Rank hold TEVA as of Q3 2013.

  • Manifold Partners reported no remaining Teva Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Manifold Partners sold 1,610 Teva Pharmaceuticals shares in Q3 2013, an estimated $63K.
  • Manifold Partners first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Manifold Partners's Teva Pharmaceuticals position peaked at $63K in Q2 2013.
  • 705 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2013.

Based on Manifold Partners's 13F filing for Q3 2013, filed 13 Nov 2013.